NCT03406832

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Prevention of Coronary Slow Flow or No-Reflow During Elective Percutaneous Coronary Intervention in Patients With Acute ST-segment Elevation Myocardial Infarction

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,000 (estimated)
• Sponsor: The First Affiliated Hospital of Zhengzhou University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Elective percutaneous coronary intervention (EPCI) is the common treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following EPCI in STEMI patients has been a serious and common complication that closely related to the incidence of major adverse cardiovascular events (MACE) and affected patients' prognosis. No reflow is a multi-factorial phenomenon. And its preventive and therapeutic effects are not satisfactory. This prospective randomized controlled study aimed to compare favorable effects of Nitroprusside versus Tirofiban on the prevention of slow flow / no-reflow phenomenon during EPCI.

Conditions

• ST Segment Elevation Myocardial Infarction
• Elective Percutaneous Coronary Intervention

Interventions

Type	Name	Description
DRUG	Nitroprusside Sodium	Intracoronary infusion 50\~100μg each time (repeated)
DRUG	Tirofiban Hydrochloride	Intracoronary infusion 10μg/kg for single time
DRUG	Heparinized saline	Intracoronary infusion 2ml for single time

Timeline

• Start date: 2018-01-08
• Primary completion: 2019-06-30
• Completion: 2019-12-31
• First posted: 2018-01-23
• Last updated: 2019-06-07

Locations

28 sites across 1 country: China